Thrombocytopaenia and neutropaenia associated with daptomycin USE

Leyra, Fernando; Perez-Chuliá, Nuria; Jofré, Cristina; Suárez-Gonzalo, Luis; Ser, Natalia Peña del; Moreno, Isidro

doi:10.1179/1973947815y.0000000032

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon discontinuation of daptomycin, the patient had resolution of her neutropenia with a reported WBC of 5 x 10 -3 /µL and an ANC of 3.4 x 10 -3 /µL. Furthermore, Leyra and colleagues described a case of a 75-year-old woman who developed both neutropenia and thrombocytopenia associated with prolonged, high dose daptomycin (10 mg/kg/day) in the management of endocarditis 4 . This patient developed her blood dyscrasias on the 28 th day of daptomycin and cefepime therapy.…”

Section: Discussionmentioning

confidence: 99%

“…The use of daptomycin, a cyclic lipopeptide antibacterial agent approved for use in the management of complicated skin and skin structure and Staphylococcus aureus bloodstream infections, has increased due to greater rates of drug-resistant gram-positive bacterial infections 2 . Despite being an appropriate agent for management of such drug-resistant gram-positive infections in neutropenic patients, several case reports describe the development of neutropenia or thrombocytopenia secondary to daptomycin use [3][4][5][6] . We report a case of neutropenia attributed to the use of daptomycin in a patient with an Enterococcus faecium pressure ulcer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Case of Rapid-onset Daptomycin-induced Neutropenia

Lancaster¹,

Vaudo²,

Singh³

2017

Am J Hosp Med

View full text Add to dashboard Cite

A 75-year-old Caucasian woman was transferred to a tertiary academic medical center for management of a foul smelling, non-draining, unstageable sacral pressure ulcer. Upon admission, the patient's laboratory data was notable for a white blood cell count (WBC) of 14.90 x 10-3 /µL and absolute neutrophil count of 12.24 x 10-3 /µL. After a complicated hospital course the patient was initiated on daptomycin 6 mg/kg (300 mg) daily in response to wound cultures detecting Enterococcus faecium susceptible only to daptomycin and linezolid. Starting 96 hours after daptomycin initiation, there was a profound reduction in the patient's WBC, reaching a nadir of 1.63 x 10-3 /µL after 12 days of therapy. Prior to documented resolution of her blood dyscrasia the patient was transferred to hospice care and use of antimicrobial therapy was withdrawn. The Naranjo Adverse Drug Reaction Probability Score demonstrated a probable relationship (score equal to 6) between daptomycin and the development of neutropenia. Unlike previous reports of daptomycin-induced neutropenia and/or thrombocytopenia, where patients received prolonged courses of daptomycin with doses ranging from 6-10 mg/kg, this case describes a much more rapid onset of neutropenia that occurred at a dose of 6 mg/kg/day. This case reports highlights the risk for daptomycin to induce neutropenia in patients receiving traditional dosing, not just at higher doses, and within a shorter time-frame than previously documented. Healthcare providers should be cognizant of this adverse reaction, and diligent in monitoring for adverse events, associated with daptomycin use even when used for short courses or at traditional doses.

show abstract

Section: Discussionmentioning

confidence: 99%